Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Vladimirov, I. Chernyayev (Khanty-Mansjisk, Yekaterinburg, Russian Federation). Relationship between exposure with drug resistant tuberculosis and developing new resistant cases. Eur Respir J 2009; 34: Suppl. 53, 203

Member's Comments

No comment yet.

Related content which might interest you: Treatment of resistant tuberculosis in patients having isolates resistant to multiple antituberculosis drugs Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010 Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis Source: Eur Respir J, 50 (5) 1701552; 10.1183/13993003.01552-2017 Year: 2017 Frequency of side effects among patients with drug resistant tuberculosis (DR-TB) by resistance pattern in a high burden country. Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Increasing incidence of fluoroquinolone resistant tuberculosis in Bombay Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005 Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003 Rapid molecular detection of rifampicin and isoniazid resistance and identification of mutations in resistant genes of multi-drug resistant tuberculosis (MDR-TB) patients Source: Annual Congress 2011 - Novel strategies for the diagnosis of tuberculosis Year: 2011 Drug resistance profiles of mycobacterium tuberculosis isolates in MDR pulmonary tuberculosis from a high burden developing country Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007 Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Treatment outcome of multidrug resistant tuberculosis with second line drugs Source: Eur Respir J 2001; 18: Suppl. 33, 314s Year: 2001 Treatment outcome of multi-drug resistant tuberculosis Source: Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis Year: 2004 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009 Treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) with different pattern of resistance Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004 Is standardized treatment appropriate for non-XDR multiple drug resistant TB? Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Treatment possibilities of multi-drug resistant (MDR) tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 525s Year: 2003 Evaluation of therapeutic response in isoniazid resistant TB Source: Eur Respir J 2006; 28: Suppl. 50, 846s Year: 2006 Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012